Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

NAFLD
Diabetes Mellitus, Type 2
Hypertriglyceridemia
Fatty Liver, Nonalcoholic

Interventions

DRUG: Placebo
DRUG: ISIS 703802 40 mg
DRUG: ISIS 703802 80 mg
DRUG: ISIS 703802 20 mg

Sponsor

Akcea Therapeutics

Collaborators

[object Object]